Griffin: Accessing functional antibodies from serum without B cells
Griffin is a platform for sequencing polyclonal antibodies using mass spectrometry. Since 2009, Abterra Biosciences founders and employees have been developing novel methods for sequencing antibody proteins directly. Our monoclonal antibody sequencing service, Valens, has been used to successfully sequence hundreds of antibodies without the need for B cells. Now, with Griffin, we can sequencing complex mixes of antibodies directly from patient serum, or from immunized animals.
Watch our CEO, Dr. Natalie Castellana’s presentation on Unlocking the Serum Antibody Repertoire: Accessing Functional Antibodies without B Cells to learn how Griffin works.
Click below to watch the presentation.
Related Posts
Llama Immune Repertoire Profiling
Alicanto® is Abterra Biosciences' proprietary antibody discovery platform that mines the entire immune response to identify diverse, functional antibodies. For an overview of the proteogenomic process, read more about Alicanto®. The infographic below was created using...
PEGS Boston Summit 2021 Presentation
Abstract: Next-generation sequencing of antibody repertoires has provided new insights into natural immune responses. The correlation between the B-cell receptor repertoire and the serological antibody repertoire has only been analyzed in a small number of studies. ...
Abterra Bio Seattle Angel Conference Winner
We’re excited to announce that Abterra Bio has been chosen as the Winner of the 19th Seattle Angel Conference and the Audience Favorite Award. This year, there were 81 start-up companies from all over the US that had applied. The selection process took around 2-3...
Get In Touch